Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 612 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: iron Clear all

Conditions: Postural Orthostatic Tachycardia Syndrome, Acute Hepatic Porphyria
Interventions: Autonomic Function Testing, Genetic Testing, Urine Testing, Blood laboratory Testing; Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Anemia, Critical Illness
Interventions: Iron Dextran, Erythropoietin (EPO); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Iron Deficiency, Restless Leg Syndrome
Interventions: Probiotics, Placebo; Dietary Supplement
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: 5 Years to 18 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Metastatic Solid Tumors, Stage 4 Cancer
Interventions: The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.; Device
Lead sponsor: New Phase Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Malignant Neoplasms of Mesothelial and Soft Tissue, Gastrointestinal Stromal Tumor With Neurogenic Differentiation
Interventions: Ferric Carboxymaltose, Iron Supplements, Questionnaire; Drug · Dietary Supplement · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anemia
Interventions: Oral Iron, sodium ferric gluconate; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 8
States / cities: Hot Springs, Arkansas • Orange County, California • Simi Valley, California + 5 more

Conditions: Functional Iron Deficiency, Trauma, Anemia
Interventions: Iron sucrose, Oxandrolone, IV iron placebo, Oxandrolone placebo; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Cystic Fibrosis, Anemia, Iron-Deficiency
Interventions: Ferrous sulfate 325mg, Placebo; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Portland, Maine • Lebanon, New Hampshire

Conditions: Iron Deficiency, Anemia, Kidney Disease
Interventions: Ferumoxytol, Iron Sucrose; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Tempe, Arizona • Chula Vista, California • Mountain View, California + 11 more

Conditions: Pregnancy Related, Anemia, Iron Deficiency
Interventions: Ferumoxytol Injection [Feraheme], Ferrous Sulfate; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Iron Deficiency
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Energy
Interventions: Heart & Soil Lifeblood; Dietary Supplement
Lead sponsor: Efforia, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Insulin Resistance, Healthy, Obesity
Interventions: Phentolamine, Saline, Sodium Nitroprusside; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pregnancy
Interventions: Intravaneous iron(low molecular weight iron dextran); Drug
Lead sponsor: Auerbach Hematology Oncology Associates P C; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anemia, Cooley's, Beta-Thalassemia, Hematologic Diseases, Thalassemia, Osteoporosis, Iron Overload, Hypertension, Pulmonary
Interventions: Deferoxamine, Deferiprone, Arginine, Sildenafil, Decitabine; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 1 Year to 75 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 4
States / cities: Oakland, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Helicobacter Pylori Infection
Interventions: BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE, MATCHING PLACEBO; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Iron Deficiency Anemia (IDA)
Interventions: Ferric Bepectate IV Injection, Ferric Carboxymaltose Injection [Ferinject], Ferric Carboxymaltose Injection [Injectafer®]; Drug
Lead sponsor: AFT Pharmaceuticals, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 1,366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Coral Gables, Florida • Melbourne, Florida • The Villages, Florida + 4 more

Conditions: Autoimmune Hepatitis
Interventions: LiverMultiscan; Device
Lead sponsor: Perspectum; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Anemia, Diamond-Blackfan
Interventions: Eltrombopag; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
Interventions: Control: Lacated Ringers, Apocynin, Allopurinol, BH4, NG Nitro L Arginine Methyl Ester, Sodium Nitroprusside, Acetyl-ß-methylcholine chloride; Drug
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 35 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Iron-deficiency, Iron Deficiency Anemia
Interventions: phytic acid; Dietary Supplement
Lead sponsor: Kansas State University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Manhattan, Kansas

Conditions: Chronic Hepatitis C
Interventions: Ribavirin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anemia, Hemosiderosis
Interventions: Deferasirox; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 5
States / cities: Oakland, California • Stanford, California • Boston, Massachusetts + 2 more

Conditions: Adult Brain Glioblastoma
Interventions: Gadolinium, Ferumoxytol Non-Stoichiometric Magnetite, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Diffusion Weighted Imaging, MRI-Based Angiogram; Drug · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome

Practical Anemia Bundle for SusTained Blood Recovery

Probiotics in the Treatment of Iron Deficiency in Children With Restless Leg Syndrome

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.

Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy

Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone

Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis

A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease

Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia

Neuroimaging of Donor Iron Deficient Study

Evaluating Heart & Soil's Lifeblood on Iron and Energy Levels

Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity

Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

Helicobacter Pylori and Body Iron in Adults

A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia

AIH Risk Stratification With Multiparametric MRI

Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag

The Effect of Antioxidants on Skin Blood Flow-BH4

Cystatin SN Binds to Phytic Acid and Predicts Non-heme Iron Bioavailability

Long-Term Therapy With Ribavirin for Chronic Hepatitis C

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy